EUCTR2016-002146-23-ES进行中（未招募）1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 354
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject or legally authorized representative has provided written informed consent;
- •2.Subject is 18 years of age or older at the time of enrollment;
- •3.Subject is currently hospitalized and is mechanically ventilated endotracheally and, in the Investigator’s opinion, will require ongoing ventilator support for at least 48 hours;
- •NOTE: Subjects with a chronic tracheostomy are not eligible.
- •4.Female subjects must not be pregnant or lactating. Female subjects of childbearing potential must have a documented negative pregnancy test at Screening. Female subjects may be enrolled on the basis of a negative urine pregnancy test, pending the result of a negative serum pregnancy test prior to randomization; and
- •5.Female subjects of childbearing potential and non-surgically sterile male subjects who are sexually active must agree to use an approved highly effective form of contraception from the time of informed consent until 165 days post dose. Approved forms of contraception include hormonal intrauterine devices (IUD), hormonal contraceptives (oral birth control pill, depot, patch or injectable) together with supplementary double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
- •NOTE: The following categories define women who are NOT considered to be of childbearing potential:
- •Premenopausal female with 1 of the following:
- •o Documented hysterectomy,
- •o Documented bilateral salpingectomy, or
- •o Documented bilateral oophorectomy, or
- •Postmenopausal female, defined as having amenorrhea for at least 12 months without an alternative medical cause.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 254
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1.Subject has received intravenous (IV) immunoglobulin therapy within 4 months prior to Screening;
- •2.Subject has a chest X-ray or thoracic computed tomography (CT) scan showing new or progressive infiltrates consistent with the diagnosis of pneumonia;
- •3.Subject demonstrates both of the following:
- •a.Need for acute changes in ventilator support to enhance oxygenation or to the amount of positive end-expiratory pressure; and
- •NOTE: Changes made in ventilator support due to day to day maintenance other than those changes made to improve oxygenation will not exclude a subject from participation in the study.
- •b.New onset of purulent suctioned respiratory secretions;
- •4.Subject has a condition at baseline (e.g., traumatic chest injury with paradoxical breathing OR congestive cardiac failure with bilateral infiltrates) which precludes the radiologic diagnosis of HABP/VABP;
- •5.Subject has known pulmonary heavy colonization or infection with a Gram-negative organism;
- •NOTE: Randomization should not be delayed while waiting for Gram-negative results if heavy colonization with S. aureus has been confirmed.
- •6.Subject has been diagnosed with neutropenia (absolute neutrophil count 500/mm3);
- •7.Subject has a severe non-pulmonary source of infection which, in the Investigator’s opinion, would interfere with the conduct of the study or jeopardize the subject’s safety;
- •8.Subject is currently on either continuous veno- venous hemodialysis or extracorporeal membrane oxygenation;
- •9.Subject has been previously exposed to ASN100 or ASN-1 or ASN-2, individually;
- •10.Subject has a known hypersensitivity to ASN100 or any of its excipients;
- •11.Subject has received any investigational product within 30 days prior to the Screening Visit (or 5 half-lives of the investigational product, whichever is longer);
- •12.Subject has, in the opinion of the Investigator, a high probability of death within 72 hours of randomization;
- •13.Subject is, in the opinion of the Investigator, not able or willing to comply with the protocol;
- •14.Any disease or condition (medical or surgical) which, in the opinion of the Investigator, might compromise the hematologic, cardiovascular, pulmonary, renal, endocrine, autoimmune, gastrointestinal, hepatic, skeletal, or central nervous system; or other conditions that, in the opinion of the Investigator, would interfere with the absorption, distribution, metabolism or excretion of ASN100, or would place the subject at increased risk; or
- •15.Subjects with (suspected) previous diagnosis of cytokine release syndrome.
研究者
相似试验
进行中（未招募）
1 期
Study of ASN100 in Ventilated SubjectsEUCTR2016-002146-23-HUArsanis, Inc.354
进行中（未招募）
1 期
The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE)Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)CTIS2024-510872-18-00Merck Healthcare KGaA508
已完成
2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentPMR10003816polymyalgia rheumaticaNL-OMON54200AbbVie Deutschland GmbH & Co. KG15
进行中（未招募）
不适用
Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR MutatioMedDRA version: 13.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2009-010261-23-Outside-EU/EEAVertex Pharmaceuticals Incorporated140
进行中（未招募）
不适用
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 InhibitorMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-003439-41-DKVertex Pharmaceuticals Incorporated40